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Marie-Hélène Louis1,2,3, Laurent Poulain1,2,3 and Philippe Icard1,2,3,4Abstract
The inhibition of two major anti-apoptotic proteins, Bcl-xL and Mcl-1, appears essential to destroy chemoresistant
cancer cells. We have studied their concomitant inhibition, using ABT 737 or siRNA targeting XL1 and citrate, a
molecule which reduces the expression level of Mcl-1.
Two cisplatin-chemoresistant ovarian cell lines (SKOV3 and IGROV1-R10) were exposed to ABT 737 or siRNA
targeting XL1 and citrate at various individual concentrations, or combined. Cell proliferation, cell cycle repartition
and nuclear staining with DAPI were recorded. Western blot analyses were performed to detect various proteins
implied in apoptotic cell death pathways.
Mcl-1 expression was barely reduced when cells were exposed to citrate alone, whereas a mild reduction was
observed after ABT 737 treatment. Concomitant inhibition of Bcl-xL and Mcl-1 using ABT 737 or siXL1 associated
with citrate was far more effective in inhibiting cell proliferation and inducing cell death than treatment alone.
Given that few, if any, specific inhibitors of Mcl-1 are currently available, anti-glycolytic agents such as citrate could
be tested in association with synthetic inhibitors of Bcl-xL.
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Chemoresistance increases the seriousness of cancer,
since, in the absence of effective chemotherapy, other
treatment modalities (surgery, radiotherapy) are often
doomed to failure, especially when cancer is diagnosed
at an advanced stage. For ovarian cancer, which is the
fifth most frequent cause of tumour death in women,
the 5-year survival rate for stage III and IV disease
(representing around 75% of cases) is approximately
20% - 30%. These disappointing results are mainly due
to intrinsic chemoresistance or to progressively ac-
quired resistance, despite a good response to surgery
and to first-line platinum-based chemotherapy [1,2].
When active, chemotherapies lead to the apoptotic
death of cancer cells [3,4]. Apoptosis is controlled by
members of the BCL-2 family, which promote or inhibit* Correspondence: hubert.lincet@unicaen.fr
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reproduction in any medium, provided the orthis process [5]. The main anti-apoptotic members are
Bcl-2, Mcl-1 and BCL-xL, whereas the main pro-death
members are Bax, Bak, Bad and Bim [6,7]. Overexpression
of anti-apoptotic Bcl-2 family proteins has been reported
as contributing towards cell survival and drug resistance
in a variety of human malignancies [8,9]. In various can-
cers, Bcl-xL and Mcl-1 are frequently overexpressed [8],
suggesting that resistance to apoptosis could imply these
two key anti-apoptotic factors. Furthermore, Bcl-xL and
Mcl-1 are frequently associated with chemotherapeutic
resistance and relapse [9,10]. Therefore, anti-apoptotic
strategies, such as concomitant inhibition of Bcl-xL and
Mcl-1 are expected to play a potentially important role in
the near future to overcome drug resistance in certain
cancers [9,11,12]. Given that Bcl-xL inhibitors are cur-
rently under clinical evaluation (e.g. BH3 mimetic com-
pounds such as antimycin A3, gossypol, HA14-1 [13] or
ABT-737) [14-16]), and that there are few or no available
specific inhibitors of Mcl-1 [17], the discovery of new
Mcl-1 inhibitors is of crucial interest.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cycle (TCA), which acts as an “energy gauge” inside the
cell since, when in excess, it inhibits glycolysis by allo-
steric retro-control on phosphofructokinase (PFK). This
enzyme catalyses the first irreversible reaction of glycoly-
sis and constitutes the main control checkpoint of this
pathway. Because glycolysis furnishes essential interme-
diates (such as ribose, glycerol, serine …) required for
cancer cell proliferation and a significant share of ATP,
especially in hypoxic conditions [18-21], its blockage
could arrest cancer cell growth [22-25]. When citrate is
abundant, PFK activity is virtually switched off, leading
to a slowdown in TCA. Interestingly, citrate leads to
early down-expression of Mcl-1 [13;28].
ABT-737 is a small chemical molecule that mimics the
direct binding of Bad to Bcl-2, Bcl-xL and Bcl-w, but not
to Mcl-1 [26]. It has demonstrated preclinical activity as
a single agent in a wide variety of cancer cells, such as
hematopoietic cell lines [27-30] and, to a lesser extent,
solid tumour cell lines [32;34–37]. However, ABT-737 is
unable to induce cell death as a single agent in other
tumour models, such as prostate cancer [38]. This rela-
tive resistance has previously been linked to a persis-
tence of Mcl-1 expression [38–40]. Our work confirms
the primordial importance of the concomitant inhibition
of the two key anti-apoptotic proteins, Mcl-1 and Bcl-xL.
Citrate, which reduces the expression of Mcl-1, drama-
tically increases cell death in chemoresistant human ova-
rian carcinoma cell lines exposed to interfering RNA
targeting Bcl-xL or ABT-737.
Materials and methods
Cell line and culture
The SKOV3 cell line was established from a human
ovarian adenocarcinoma and was obtained from ECACC
(Sigma-Aldrich, Saint Quentin Fallavier, France). The vari-
ant, the highly chemoresistant cell line IGROV1-R10, was
established through a protocol that mimics the clinical
protocol of CDDP treatment leading to a complete CDDP-
refractory cell state [31]. These two cell lines were grown
in an RPMI medium supplemented with 4,500 mg/L
glucose, 2 mM Glutamax™, 1 mM sodium pyruvate, 10%
foetal calf serum, 33 mM sodium bicarbonate (Invitrogen,
Cergy-Pontoise, France). Cells were maintained at 37°C
in a 5% CO2 humidified atmosphere and split twice a
week by trypsinisation.
Chemicals and schedule for treatment
siRNA synthesis and transfection
All siRNAs used in these studies were chemically syn-
thesised by Eurogentec (Liege, Belgium) and received as
annealed oligonucleotides. The sequence for the double-
stranded RNA used to inhibit XL1 expression (noted
siXL1) is: sense 5′-AUUGGUGAGUCGGAUCGCA-3′and anti-sense 5′-UGCGAUCCGACUCACCAA-3′. siXL1
selectively targets Bcl-xL mRNA, but not Bcl-xS mRNA.
The sequence for the control siRNA siCTRL is: sense 5′-
GACGUAAACGGCCACAAGU-3′ and anti-sense 5′-AC
UUGUGGCCGUUUACGUC-3′. The control siRNA bears
no homology with any relevant human genes. According
to the manufacturer’s instructions, exponentially grow-
ing cells were seeded (2.5 × 105 cells per 25 cm2 flask)
the previous day, in order to reach 30–50% confluency
at the time of transfection. Briefly, the transfecting
INTERFERin™ reagent (Polyplus Transfection, Stras-
bourg, France) was added to siRNA (20 nM), diluted in
an Opti-MEM® reduced serum medium (Invitrogen)
and complex formation was allowed to proceed for
15 min at room temperature before being applied to
cells. The following day, the cell media was changed to
remove the transfection reagent. At the indicated time,
cells were trypsinised and washed with cold PBS. Cell
pellets were used directly or stored at −80°C for later
use. At least two independent experiments were carried
out and typical results are illustrated.
The sodium citrate tribasic pH 7.5 solution was
obtained from Sigma Aldrich. 24 H after transfection,
cells were treated with citrate.
ABT-737 was provided by Selleckchem (Euromedex,
France) and stored as a stock solution in DMSO at −20°C.
Exponentially growing cells were exposed to citrate in
complete growth medium for 24 H then incubated for
24 H with or without an ABT-737 supplement.
Nuclear morphology study
After treatment, detached cells were collected separately
and adherent cells were dissociated by trypsin/EDTA.
The cells were then pooled and collected on a polylysine-
coated glass slide by cytocentrifugation, fixed in an etha-
nol/chloroform/acetic acid solution (6:3:1) and incubated
for 15 min at room temperature with a 1 μg/mL DAPI
aqueous solution (Boehringer Mannheim, Germany).
Slides were thereafter extensively washed in distilled water,
mounted in Mowiol (Calbiochem, Meudon, France) and
analysed under a fluorescence microscope.
Analysis of cellular DNA content by flow cytometry
Cells were prepared for flow cytometry as detailed previ-
ously [14]. Briefly, adherent and detached cells were
pooled, washed in PBS and fixed in 70% ethanol,
centrifuged then incubated for 30 min at 37°C in PBS. Pel-
lets were then collected and resuspended for staining with
propidium iodide (PI) using the DNA Prep Coulter Re-
agent Kit (Beckman-Coulter, Villepinte France). Samples
were then analysed using an EPICS XL flow cytometer
(Beckman Coulter, Villepinte, France) equipped with an
argon laser at 15 mW, using 488 nm excitation. EXPO 32





































































Figure 1 Effect of citrate on two ovarian cancer cell lines:
SKOV3 (A) and IGROV1-R10 (B). Evolution of viable cells up to
72 H after continuous exposure to 5, 10 and 20 mM of citrate (CT).
Exponentially growing SKOV3 cells (A) or IGROV1-R10 cells (B) were
treated with different citrate concentrations in the medium with
SVF. The number of viable cells was assessed by the trypan blue
exclusion test at various times after treatment. Results are expressed
as the mean values of two independent experiments. Analysis of
variance was used to determine significance. **: p < 0.05; ***:
p < 0.001.
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(qRT-PCR)
Total RNA was isolated from ovarian carcinoma cell
lines using Trizol (Invitrogen). RNA quantity and quality
were assessed using the NanoDropTM 2000 spectropho-
tometer (Thermo Scientific, Palaiseau, France). qRT-PCR
was performed as previously described [15]. Correspon-
ding custom inventoried (ID: Hs00172036_m1 for Mcl-1
and Hs99999905_m1 for GAPDH) TaqMan® Gene Ex-
pression. All PCR amplification reactions were carried
out in triplicate and detection was performed on an
Applied ABI Prism 7500 Fast PCR system (Applied
Biosystems). GAPDH was used as a housekeeping refe-
rence gene for normalisation.
Western immunoblotting
Adherent cells were rinsed with deionised water and
lysed with a lysis buffer (pH 8.8 30 mmol.L-1 Tris buffer
containing 6 mol.L-1 urea, 2 mol.L-1 thiourea, 2% CHAPS,
1X protease inhibitor Mix). Western blot analysis was car-
ried out as previously described [16]. The membrane
was either incubated overnight at 4°C in T-TBS-milk
5% with the following primary antibodies: anti-PARP
(1: 1000, Cell Signalling Technology, Beverly, USA),
anti-Bcl-xL (1: 1000), anti-Mcl-1 (1: 750, Cell Signalling
Technology, Beverly), USA anti-actin (1: 5000, Sigma-
Aldrich, Saint Quentin Fallavier, France), anti-cleaved
caspase 3 (1: 1000, Cell Signalling Technology, Beverly,
USA). After three washes with T-TBS and one with TBS,
immunoreactivity was detected by enhanced chemilumi-
nescence (ECL Prime kit, GE Healthcare).
Results
Effect of citrate alone
We first studied the kinetic effect of continuous expo-
sure to various concentrations of citrate on two human
ovarian carcinoma cell lines, SKOV3 (Figure 1A) and
IGROV1-R10 (Figure 1B). As shown in Figure 1A and B,
cells exposed to 20 mM citrate demonstrated a high
cytotoxic effect from 24 H to 72 H, in contrast with cells
exposed to 5 mM citrate. At the 5 mM concentration,
the citrate effect is dependent on the time. 72 H after
exposure at 5 mM citrate, the inhibition percentage is
68% and 72% in SKOV3 or IGROV1-R10 cells respec-
tively, compared to control cells.
With regard to cellular morphology, distribution in the
different phases of the cell cycle and DAPI nuclear stai-
ning, SKOV3 cells did not show a marked difference com-
pared to control cells (data not shown). In contrast,
IGROV1-R10 cells showed cell rounding, which was
concentration-dependent and time-dependent, beginning
as early as 24 H (Figure 2A). This phenomenon was asso-
ciated with a slight accumulation of cells in G2/M phase
24 H after exposure at 20 mM (25.6% 20 mM citrate vs20.8% control) (Figure 2B). Moreover, at this concentra-
tion, a subG1 peak appeared, which is characteristic of
apoptotic cells, 24 H after treatment by 20 mM citrate;
14.6% were in subG1 compared to 1.3% in control cells.
This phenomenon persists over time, 72 H after the same
treatment; 18.6% were in subG1 versus 5.9% in control
cells (Figure 2B). At the lower concentration of 5 mM
citrate, a slight subG1 peak appeared at 24 H (6.4%)
and increased at 72 H (11.1%) (Figure 2B).
In these two ovarian carcinoma cell lines, western blot
analysis showed that exposure of SKOV3 cells to citrate
at 20 mM led to a decrease in the expression of the anti-
apoptotic protein Mcl-1, as from 6 H compared to con-
trol cells (Figure 2C). This effect was associated with a
Figure 2 (See legend on next page.)
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Figure 2 Effect of various citrate (CT) concentrations (5, 10, 20 mM) in IGROV1-R10 cells after 24 and 72 H exposure. (A) The
morphological features of cell layers were observed by photon microscopy. (B) DNA content was determined at 24 H or 72 H by flow cytometry
after propidium iodide staining (for each condition, percentages of cells in the different phases of the cell cycle are indicated). Protein expression
levels of PARP cleavage and caspase 3 cleavage and Mcl-1 and Bcl-xL on SKVO3 cells (C) and on IGROV1-R10 cells (D) by western blot analysis in
response to citrate at 6 and 24 H. Mcl-1 mRNA expression in SKOV3 cells (E) and IGROV1-R10 cells (F) treated with citrate for 6 H or 24 H was
assessed using real-time quantitative reverse transcription PCR. GAPDH was used as a housekeeping reference gene for normalisation. Each
relative mRNA expression level was calculated in comparison to the control cell expression level.
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(Figure 2C). In the other IGROV1-R10 cell line, we also
observed a decrease in Mcl-1 expression after exposure
to citrate at 20 mM, with nearly complete extinction of
this anti-apoptotic protein at 24 H. At this stage, a slight
decrease in Mcl-1 expression is worthy of note (Figure 2D).
Cleavage of PARP and caspase 3 were also detected under
the same conditions (Figure 2D). In both cell lines, we
observed no significant modification in the expression
of the other anti-apoptotic protein, Bcl-xL, indepen-
dently of concentrations or time (Figure 2C and D).
The analysis of Mcl-1 mRNA by qRT-PCR showed in
SKOV3 cells, 6 H after treatment to 5 – 20 mM citrate,
the Mcl 1 mRNA level was not modified. An induction of
this transcript was observed at 24 H with the same doses
(Figure 2E). In our other cell model, IGROV1-R10, the
Mcl-1 mRNA level was slightly induced after 6 H of treat-
ment with 10 to 20 mM citrate. This induction increased
at 24 H after exposure to the same doses (Figure 2F). A
slight increase in Mcl-1 mRNA at 24 H after exposure to
5 mM citrate in IGROV1-R10 cells was also observed
(Figure 2F).
Effect of concomitant inhibition of Bcl-xL and Mcl-1
With siRNA targeting Bcl-xL
Cells were transfected with siRNA (siXL1 or siCTRL),
24 H before exposure to citrate at 10 mM. As depicted in
Figure 3, for SKOV3 cells, citrate at 10 mM and siXL1 sig-
nificantly reduced (87%) the percentage of viable SKOV3
cells, compared to control cells (Figure 3A). 10 mM
Citrate or siXL1 treatment alone inhibits the viability of
59% and 43% of cells respectively. The DNA histogram
(Figure 3B) showed a mild increase in the subG1 peak
which is a characteristic of apoptotic cells (15% after cit-
rate/siXL1 association vs. 5% after citrate alone or 7% after
siXL1 alone). Nuclear staining with DAPI revealed an
increased number of remnant cells with “ghost nuclei”
(Figure 3C). A combination of siCTRL and citrate did not
reveal any difference compared to cells treated with citrate
alone (Figure 3A,B,C).
For IGROV1-R10 cells (Figure 4), citrate at 10 mM as-
sociated with siXL1 led to a 91% reduction in viable cells
compared with the control, which was significantly more
important than citrate alone or siXL1 alone, which re-
spectively led to a reduction of 62%, and 43%. 72 H afterexposure to citrate and siXL1, IGROV1-R10 cells
showed significant cell rounding and cell death in the
flask culture (data not shown). This phenomenon was
confirmed by the DNA histogram, which revealed
a strong subG1 peak (44% of cells) at this stage
and under these treatment conditions (siXL1 and cit-
rate) (Figure 4B). DAPI staining showed few normal
nuclei, whereas numerous “ghost nuclei” were observed
(Figure 4C).
In both cell lines, western blot analysis confirmed the
efficacy of siXL1 to strongly inhibit the expression of
Bcl-xL up to 72 H after transfection, compared with
SKOV3 cells (Figure 5A) and IGROV1-R10 cells (Figure 5B)
transfected with siCTRL. In both cell lines, we also con-
firmed that 10 mM citrate reduced the expression of
Mcl-1 48 H after treatment. As shown in Figure 5A and
B, strong activation of caspase 3 leading to the total
cleavage of PARP was only observed after cell exposure
to combined treatment.ABT-737 treatment
We added ABT-737, a BH3 mimetic compound to block
Bcl-xL activity, to the cell culture 24 H after citrate ex-
posure. Since efficacy was more marked in IGROV1-R10
cells, we focused our results on this cell line. This com-
bined treatment induced strong cytotoxicity, with very
few viable cells on the flask culture (Figure 6A). Nuclear
morphology and the DNA histogram revealed very
strong apoptotic cell death, with numerous nuclear
fragments and DNA remnants (73% in subG1 peak;
Figure 6C). This combined treatment led to the almost
complete disappearance of cells in G2/M (2.5%), with a
drastic reduction in G1 phase cells (15%) (Figure 6C).
DAPI nuclear staining confirmed the DNA histogram; we
exclusively observed “ghost nuclei” in response to citrate/
siXL, whereas citrate or siXL1 alone induced some apop-
totic morphologies and normal nuclei (Figure 6B). In
contrast, cells exposed to citrate or ABT −737 alone did
not demonstrate the same efficacy in inducing cell death
(Figure 6C). Citrate 10 mM led to a stronger reduction in
Mcl-1 expression when associated with ABT-737, com-
pared with citrate alone (Figure 6D). This combined treat-
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Figure 3 Effect of siXL1 in response to citrate in the SKOV3 cell line. Cells were transfected with 20 nM siXL1 24 H before exposure to
10 mM of citrate and cultured for an additional 48 H (i.e. 72 H post transfection). Evolution of viable cells up to 72 H (A) in SKOV3. Results are
expressed as a percentage of viable cells compared to the 100% control cells. Results are expressed as the mean values of two independent
experiments. Analysis of variance was used to determine significance. **: p < 0.05; ***: p < 0.001. (B) Cell cycle repartition was studied by flow
cytometry after propidium iodide staining at 72 H after transfection in SKOV3 cell lines. (C) The nuclear morphology of SKOV3 cells was analysed
by DAPI staining at 72 H. Bars 20 μm.
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In the absence of effective chemotherapy, other anti-
cancer treatment modalities (surgery, radiotherapy) are
most often doomed to failure, as demonstrated for ovarian
cancers, for which 5-year survival rates are generally poor,
as for many other solid cancers. Hypoxic cells are believed
to play an important role in chemoresistance [17-19],since these cells may adopt resistance strategies, such as
enhanced glycolysis, glutaminolysis, overexpression of
anti-apoptotic factors, etc., to survive harsh chemotherapy
conditions [20,21].
Overexpression of anti-apoptotic proteins such as Bcl-xL
and Mcl-1 have been reported to greatly contribute to cell
survival and drug resistance in various human cancers
BControl 
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Control 
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Figure 4 Effect of siXL1 on response to citrate in the IGROV1-R10 cell line. Cells were transfected with 20 nM siXL1 24 H before exposure to
10 mM of citrate and cultured for an additional 48 H (i.e. 72 H post transfection). (A) Evolution of viable cells up to 72 H in IGROV1-R10. Results
are expressed as a percentage of viable cells compared to the 100% control cells. Results are expressed as the mean values of two independent
experiments. Analysis of variance was used to determine significance. **: p < 0.05; ***: p < 0.001. (B) Cell cycle repartition was studied by flow
cytometry after propidium iodide staining at 72 H after transfection in IGROV1-R10 cell lines. (C) Nuclear morphology of IGROV1-R10 cells was
analysed by DAPI staining at 72 H. Bars 20 μm.
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proteins have consequently been shown to overcome drug
resistance [11;14].
With this in mind, Bcl-xL inhibitors, such as ABT-737,
are currently under clinical evaluation as BH3 mimetic
compounds, and few or no specific inhibitors of Mcl-1
are available [45;46]; the discovery of new Mcl-1inhibitors is therefore of crucial importance. Since we
observed that citrate, an inhibitor of PFK, reduces Mcl-1
expression [11], we chose to test citrate in association
with a specific siRNA targeting Bcl-xL or ABT-737.
Our results confirm, for the two ovarian cancer cell lines
studied, the efficiency of citrate in decreasing Mcl-1 expres-







































































































Figure 5 Protein expression in SKOV3 (A) and IGROV1-R10 (B).
Levels of PARP cleavage and caspase 3 cleavage and Mcl-1 and Bcl-xL
were detected by western blot analysis in response to combined
treatment with siXL1 and citrate 20 mM, compared with no treatment
(control) or siGFP (siRNA control) or citrate alone at 72 H. Actin was
used as a loading control.
Lincet et al. Journal of Ovarian Research 2013, 6:72 Page 8 of 10
http://www.ovarianresearch.com/content/6/1/72[13,25]. In contrast, citrate demonstrated no significant
effect on Bcl-xL expression. The decrease in Mcl-1 pro-
tein expression but not Bcl-xL could be due to the acti-
vation of caspase 3 as described in other studies [32,33]
or by proteasome activity which degrades the Mcl-1 pro-
tein after ubiquitylation [27-30]. A recent study reported
that the inhibition of glycolysis using 2-deoxy-D-glucose
(2DG) induced intracellular ATP depletion which led to
specific down regulation of Mcl-1 through the transla-
tional control [34].
Concomitant inhibition of Mcl-1 and Bcl-xL is a highly
effective strategy to destroy chemoresistant ovarian
cancer cells, in accordance with previous studies we
have conducted on cancer cells from other cancer sites
[11;14;33]. In the two human ovarian cell lines studied,
all cells were totally destroyed after 72 H of exposure to
treatment associating siXL1 and citrate 10 mM, com-
pared to the administration of one product alone
(Figures 3 and 4). We chose to expose cells to citrate
24 h after siXL1 transfection, to allow the siXL1 suffi-
cient time to play its role. In contrast, since the blockage
of Bcl-xL activity by ABT-737 is very rapid, occurring
within two hours, we chose to administrate citrate before
ABT treatment. This association of citrate with ABT-737
seemed more efficient than the combination using siRNA
targeting Bcl-xL, and led to almost complete cell death
with nuclear apoptotic fragmentation and complete clea-
vage of PARP. Furthermore, the number of cells in G1 and
G2/M phases, likely to resume the cell cycle, was strongly
diminished. The mechanisms of cellular death in response
to citrate exposure remain to be further investigated. A
number of hypotheses can be put forward: - an increase in
N-alpha-acetylation of proteins such as caspases, sensitising
these cells to apoptosis, given that citrate is the donor of
acetyl in cells through ACLY activity [35], an activating
process that could be initiated at apical caspase 8 and 2
level [25]; a reduction in ATP synthesis due to glycolysis
inhibition by citrate effect, which in turn activates the
AMPK pathway, resulting in inhibition of the mTOR path-
way [28,30,34]. This pathway could inhibit Mcl-1 expression
via two mechanisms: - firstly, Mcl-1 could be phosphorylated
by activated GSK3 beta and then degraded by proteasome
after ubiquitylation [27-30]; - secondly, blockage of 4E-BP1
resulting in the inhibition of Mcl-1 translation [54;55].
According to our results, the first hypothesis appears the
most likely. This molecular aspect remains to be elucidated.
In conclusion, the effect of citrate on Mcl-1 expression
could usefully be associated with inhibitors of Bcl-xL,
since this strategy demonstrates a strong anti-cancer
effect on chemoresistant ovarian cancer cells. Given that
few or no specific inhibitors of Mcl-1 are currently avai-
lable, the use of citrate targeting Mcl-1 could be of major
interest for it could contribute towards the destruction of
chemoresistant cancer cells.
Figure 6 Effect of citrate on response to ABT-737 in IGROV1-R10 cell lines. Cells were treated with 10 mM citrate 24 H before exposure to
10 μM of ABT-737 and cultured for an additional 24 H (i.e. 48 H post citrate exposure). (A) Morphological features of cell layers at 72 H after
citrate exposure. (B) Nuclear morphology of IGROV1-R10 cells was analysed by DAPI staining at 72 H. Bars 20 μm. (C) Cell cycle repartition was
studied by flow cytometry after propidium iodide staining at 72 H after transfection in IGROV1-R10 cell lines. (For each condition, percentages of
cells in the different phases of the cell cycle are indicated). (D) Protein expression levels of PARP cleavage, Mcl-1 and Bcl-xL on IGROV1-R10 cells.
Actin was used as a loading control.
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